- WACKER invested over €100 million in the new mRNA facility.
- The center was built in two years and can produce 200 million vaccine doses annually.
- WACKER and CordenPharma will produce 80 million vaccine doses annually during a pandemic.
- The stand-by phase for pandemic preparedness will last at least five years.
Investment and Capacity
WACKER has opened an mRNA competence center at its biotech site in Halle, Germany, with an investment exceeding €100 million. The facility enables large-scale production of mRNA-based active ingredients, including vaccines, with an annual capacity of over 200 million doses.
Job Creation and Pandemic Preparedness
More than 100 highly qualified jobs have been created at the new center. Part of the production capacity will be allocated to the German government as part of its pandemic-preparedness plan, ensuring rapid vaccine supply when needed.
Timeline and Efficiency
The construction of the high-tech production facility was completed in just two years, showcasing significant efficiency. The center includes four new production lines, tripling the site's capacity.
Collaborations and Contracts
WACKER and CordenPharma have secured a contract with the German government to produce 80 million vaccine doses annually in the event of a new pandemic. This agreement includes an annual stand-by fee for maintaining production capacity and expertise, with the stand-by phase lasting at least five years.
Future Prospects
WACKER BIOSOLUTIONS aims to contribute around €1 billion to Group sales by 2030, with the development of the Halle site playing a crucial role in this strategy. The next milestone is the launch of a new Biotechnology Center in Munich later this year.
